Cargando…

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer

Androgen receptor (AR) signalling drives neoplastic growth and therapy resistance in prostate cancer. Recent clinical data show that docetaxel combined with androgen deprivation therapy improves outcome in hormone-sensitive disease. We studied whether testosterone and AR signalling interferes with d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mout, Lisanne, Moll, Jan M., Chen, Mingqing, de Morrée, Eleonora S., de Ridder, Corrina M. A., Gibson, Alice, Stuurman, Debra, Aghai, Ashraf, Erkens-Schulze, Sigrun, Mathijssen, Ron H. J., Sparreboom, Alex, de Wit, Ronald, Lolkema, Martijn P., van Weerden, Wytske M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722857/ https://www.ncbi.nlm.nih.gov/pubmed/32989230 http://dx.doi.org/10.1038/s41416-020-01105-y

Ejemplares similares

Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model()
por: Mout, Lisanne, et al.
Publicado: (2017)

Loss of SLCO1B3 drives taxane resistance in prostate cancer
por: de Morrée, Ellen S, et al.
Publicado: (2016)

Continued Androgen Signalling Inhibition improves Cabazitaxel Efficacy in Prostate Cancer
por: Mout, Lisanne, et al.
Publicado: (2021)

Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing
por: Van Hemelryk, Annelies, et al.
Publicado: (2021)

Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids
por: Van Hemelryk, Annelies, et al.
Publicado: (2023)

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling
por: Van Hemelryk, Annelies, et al.
Publicado: (2022)

Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response
por: Zhang, Wenhao, et al.
Publicado: (2018)

Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
por: Marques, Rute B., et al.
Publicado: (2010)

CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance
por: Langebäck, Anette, et al.
Publicado: (2019)

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines
por: Marques, Rute B., et al.
Publicado: (2011)

Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness
por: Wissing, Michel D., et al.
Publicado: (2014)

Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer
por: Moll, Jan Matthijs, et al.
Publicado: (2022)

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

Overexpression of Full-Length ETV1 Transcripts in Clinical Prostate Cancer Due to Gene Translocation
por: Gasi, Delila, et al.
Publicado: (2011)

Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models
por: van de Merbel, Arjanneke F., et al.
Publicado: (2021)

11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration
por: Snaterse, Gido, et al.
Publicado: (2021)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
por: Sieuwerts, Anieta M., et al.
Publicado: (2019)

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer
por: van Leenders, Geert J. L. H., et al.
Publicado: (2011)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

SAT-LB002 Steroid Metabolome Analysis Reveals 11-Ketotestosterone as the Most Abundant Androgen in Castration-Resistant Prostate Cancer Patients on Second-Line Therapies
por: Snaterse, Gido, et al.
Publicado: (2019)

A bypass mechanism of abiraterone‐resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling
por: Moll, Jan M., et al.
Publicado: (2019)

Patient-Derived Xenograft Models in Cancer Research
por: van Weerden, Wytske M.
Publicado: (2021)

Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer
por: Murce, Erika, et al.
Publicado: (2023)

Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634
por: Atrafi, Florence, et al.
Publicado: (2021)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors
por: Koustoulidou, Sofia, et al.
Publicado: (2022)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
por: de Kruijff, Ingeborg E., et al.
Publicado: (2019)

Radiochemical and Biological Evaluation of 3p-C-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics
por: Murce, Erika, et al.
Publicado: (2023)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

Pre- and Intraoperative Visualization of GRPR-Expressing Solid Tumors: Preclinical Profiling of Novel Dual-Modality Probes for Nuclear and Fluorescence Imaging
por: Verhoeven, Marjolein, et al.
Publicado: (2023)

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
por: Halabi, Susan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9r4vf2p6r04citrf7n8m69ldno